Literature DB >> 3841130

Effect of meals on the kinetics of etretinate.

W A Colburn, D M Gibson, L C Rodriguez, C J Buggé, H P Blumenthal.   

Abstract

Eight healthy men received 100 mg oral doses of etretinate separated by two-week washout periods in an open, randomized, crossover study. Etretinate was administered during a complete fast, with a standard high fat breakfast, a standard high carbohydrate breakfast, and 16 ounces of whole milk. Plasma samples were obtained at specific times over a 48-hour period. Plasma concentrations of etretinate as well as two of its major metabolites were determined by a specific, reverse-phase, high-performance liquid chromatography method. Plasma concentrations of etretinate were greater when administered with a high fat meal and whole milk compared to ingestion with a high carbohydrate meal or during a complete fast. In contrast, there was no increase in the plasma concentrations of the active metabolites following any of the meals. These data indicate that chronic dosing of etretinate with milk or a high fat meal compared with fasting conditions will result in higher concentrations of etretinate, which may ultimately lead to higher metabolite concentrations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3841130     DOI: 10.1002/j.1552-4604.1985.tb02881.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

Review 1.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Dose-proportional absorption of etretinate after doses of 25, 50, 75, and 100 mg.

Authors:  R J Wills; L C Rodriguez; A H Lin; C Puccini; W A Colburn
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

3.  Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Dennis B Bailey; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.